PRISMA-efficacy and safety of lixisenatide for type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

• Published in: Medicine (Baltimore) 2018-12, Vol.97 (51), p.e13710-e13710
• Main Authors: Wei, Zhen-Gang, Wang, Man-Cai, Zhang, Hui-Han, Wang, Zhe-Yuan, Wang, Gen-Nian, Wei, Feng-Xian, Zhang, Ya-Wu, Xu, Xiao-Dong, Zhang, You-Cheng
• Format: Article
• Language: English
• Subjects: Diabetes Mellitus, Type 2 - drug therapy; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Peptides - adverse effects; Peptides - therapeutic use; Randomized Controlled Trials as Topic; Systematic Review and Meta-Analysis
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000013710

We aimed to systematically evaluate the efficacy and safety of lixisenatide in patients with type 2 diabetes mellitus. PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, Google, Web of Science and the Chinese Science Citation Database were searched up to March 2018. Randomized controlled trials determining the efficacy and safety of lixisenatide in patients with type 2 diabetes mellitus were eligible for inclusion. Two authors independently extracted the data in a prespecified Microsoft Excel spreadsheet. A meta-analysis was performed using Review Manager 5.3 software. Weighted mean difference (WMD) and relative risk (RR) together with their corresponding 95% confidence intervals (CIs) were estimated, and only the random effects model was used in order to achieve a more conservative estimate of the efficacy and safety. Fourteen multicenter randomized controlled trials involving 11,947 patients were eligible for inclusion. Compared to placebo, lixisenatide could more significantly reduce the level of HbA1c (WMD=-0.44; 95% confidence interval [CI] [-0.55,-0.33]), and a higher proportion of lixisenatide-treated patients achieved the HbA1c level of